Our experts attending
Dedicated professionals committed to clinical excellence.
Meet Southern Star Research at ADA 2026 Scientific Sessions
The ADA 2026 Scientific Sessions brings together global leaders advancing diabetes and metabolic disease research—from early discovery through to late-stage clinical trials and real-world implementation.
With over 200 sessions spanning 25 topic areas, the program reflects the full complexity of diabetes today: evolving standards of care, novel therapeutic mechanisms, and the growing intersection of obesity, metabolism, and chronic disease.
If your team is developing the next generation of therapies in diabetes or metabolic disease, we welcome the opportunity to connect.
Supporting the Next Wave of Diabetes Innovation
Diabetes drug development is evolving rapidly. Advances in GLP-1 receptor agonists, amylin-based therapies, and beta-cell replacement approaches are redefining treatment strategies in diabetes—shifting expectations around glycaemic control, weight management, and long-term disease modification.
At the same time, sponsors face increasing complexity—balancing metabolic endpoints, patient heterogeneity, and global regulatory expectations.
We work alongside biotech teams as a present, capable partner—helping translate scientific innovation into well-designed early-phase trials that generate meaningful, decision-ready data.
Where We Add Value in Metabolic & Diabetes Trials
We specialise in early-phase clinical development across complex therapeutic areas, including metabolic and endocrine disorders.
- Proactive Partnership: We engage directly with your scientific and clinical strategy—anticipating operational and regulatory challenges specific to diabetes trials, from patient recruitment to endpoint selection.
- Embedded Quality: Metabolic studies demand precision in data collection, biomarker strategy, and protocol execution. We build quality into every stage to ensure data stands up to regulatory and investor scrutiny.
- Tailored Execution: From first-in-human through Phase 2, we design trials aligned to your mechanism of action, whether targeting glycaemic control, weight loss, or broader cardiometabolic outcomes.
Why Sponsors Choose Southern Star Research
As a mid-sized CRO with deep early-phase expertise, we offer:
- Strong experience in complex, mechanism-driven trials
- Regulatory insight across FDA, EMA, PMDA, and Health Canada
- Established site networks and patient access across APAC
- A delivery model that balances speed, cost efficiency, and data quality
Our focus is simple: generate high-quality data that supports confident decisions—whether progressing to later phases, securing partnerships, or raising capital.
Aligned with What Matters at ADA 2026
This year’s program highlights the pace of change in diabetes and metabolic research, including:
- 2026 Updates to ADA Standards of Care and obesity management
- Advances in GLP-1 receptor agonists and next-generation incretin therapies
- Emerging modalities, including stem cell–derived beta-cell therapies
- Novel metabolic pathways, such as amylin-based treatments
- Evolving understanding of disease heterogeneity, including malnutrition-related diabetes
- Nutrition, epidemiology, and population health trends shaping trial design
We help sponsors navigate these shifts—ensuring trial strategies remain scientifically robust, operationally feasible, and aligned with regulatory expectations.
Connect With Us at ADA 2026
If you’re advancing a diabetes or metabolic program and planning your next clinical milestone, we’d value the discussion.
Meet with our CEO and Director, Business Development at ADA 2026 Scientific Sessions to explore how we can support your study with a more responsive, insight-led CRO model.